{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:51:11Z","timestamp":1792752671886,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"crossref","award":["DE-AC02-05CH11231"],"award-info":[{"award-number":["DE-AC02-05CH11231"]}],"id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"crossref","award":["DE-AC02-05CH11231"],"award-info":[{"award-number":["DE-AC02-05CH11231"]}],"id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"crossref","award":["DE-AC02-05CH11231"],"award-info":[{"award-number":["DE-AC02-05CH11231"]}],"id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009259","name":"Institute for Translational Sciences, University of Texas Medical Branch","doi-asserted-by":"publisher","award":["2P30AG024832-16"],"award-info":[{"award-number":["2P30AG024832-16"]}],"id":[{"id":"10.13039\/100009259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24 TR002306"],"award-info":[{"award-number":["U24 TR002306"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH UL1TR001439"],"award-info":[{"award-number":["NIH UL1TR001439"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["NCATS U24 TR002306"],"award-info":[{"award-number":["NCATS U24 TR002306"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain, fever, and inflammation but have been associated with complications in community-acquired pneumonia. Observations shortly after the start of the COVID-19 pandemic in 2020 suggested that ibuprofen was associated with an increased risk of adverse events in COVID-19 patients, but subsequent observational studies failed to demonstrate increased risk and in one case showed reduced risk associated with NSAID use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 38-center retrospective cohort study was performed that leveraged the harmonized, high-granularity electronic health record data of the National COVID Cohort Collaborative. A propensity-matched cohort of 19,746 COVID-19 inpatients was constructed by matching cases (treated with NSAIDs at the time of admission) and 19,746 controls (not treated) from 857,061 patients with COVID-19 available for analysis. The primary outcome of interest was COVID-19 severity in hospitalized patients, which was classified as: moderate, severe, or mortality\/hospice. Secondary outcomes were acute kidney injury (AKI), extracorporeal membrane oxygenation (ECMO), invasive ventilation, and all-cause mortality at any time following COVID-19 diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Logistic regression showed that NSAID use was not associated with increased COVID-19 severity (OR: 0.57 95% CI: 0.53\u20130.61). Analysis of secondary outcomes using logistic regression showed that NSAID use was not associated with increased risk of all-cause mortality (OR 0.51 95% CI: 0.47\u20130.56), invasive ventilation (OR: 0.59 95% CI: 0.55\u20130.64), AKI (OR: 0.67 95% CI: 0.63\u20130.72), or ECMO (OR: 0.51 95% CI: 0.36\u20130.7). In contrast, the odds ratios indicate reduced risk of these outcomes, but our quantitative bias analysis showed E-values of between 1.9 and 3.3 for these associations, indicating that comparatively weak or moderate confounder associations could explain away the observed associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Study interpretation is limited by the observational design. Recording of NSAID use may have been incomplete. Our study demonstrates that NSAID use is not associated with increased COVID-19 severity, all-cause mortality, invasive ventilation, AKI, or ECMO in COVID-19 inpatients. A conservative interpretation in light of the quantitative bias analysis is that there is no evidence that NSAID use is associated with risk of increased severity or the other measured outcomes. Our results confirm and extend analogous findings in previous observational studies using a large cohort of patients drawn from 38 centers in a nationally representative multicenter database.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-022-01813-2","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T02:16:04Z","timestamp":1652580964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Justin T.","family":"Reese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany J.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cappelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie R.","family":"Bradwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomi L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Casiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Karlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Deer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"McMurry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Haendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Chute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moffitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Mungall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-9199","authenticated-orcid":false,"given":"Peter N.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"1813_CR1","unstructured":"COVID-19 Map - Johns Hopkins Coronavirus Resource Center. Available from: https:\/\/coronavirus.jhu.edu\/map.html"},{"key":"1813_CR2","doi-asserted-by":"publisher","first-page":"115094","DOI":"10.1016\/j.diagmicrobio.2020.115094","volume":"98","author":"E Ortiz-Prado","year":"2020","unstructured":"Ortiz-Prado E, Simba\u00f1a-Rivera K, G\u00f3mez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98:115094.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1813_CR3","doi-asserted-by":"publisher","first-page":"103722","DOI":"10.1016\/j.ebiom.2021.103722","volume":"74","author":"RR Deer","year":"2021","unstructured":"Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, et al. Characterizing Long COVID: Deep Phenotype of a Complex Condition. EBioMedicine. 2021;74:103722.","journal-title":"EBioMedicine"},{"key":"1813_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15\u20139.","journal-title":"BMJ"},{"key":"1813_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/infdis\/162.6.1277","volume":"162","author":"NM Graham","year":"1990","unstructured":"Graham NM, Burrell CJ, Douglas RM, Debelle P, Davies L. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis. 1990;162:1277\u201382.","journal-title":"J Infect Dis"},{"key":"1813_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2009.03.007","volume":"258","author":"S Bancos","year":"2009","unstructured":"Bancos S, Bernard MP, Topham DJ, Phipps RP. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol. 2009;258:18\u201328.","journal-title":"Cell Immunol"},{"key":"1813_CR7","doi-asserted-by":"publisher","first-page":"m1614","DOI":"10.1136\/bmj.m1614","volume":"369","author":"I Torjesen","year":"2020","unstructured":"Torjesen I. Ibuprofen can mask symptoms of infection and might worsen outcomes, says European drugs agency. BMJ. 2020;369:m1614.","journal-title":"BMJ"},{"key":"1813_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.therap.2020.05.003","volume":"75","author":"J Micallef","year":"2020","unstructured":"Micallef J, Soeiro T, Jonville-B\u00e9ra A-P. French Society of Pharmacology, Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. 2020;75:355\u201362.","journal-title":"Therapie"},{"key":"1813_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1378\/chest.09-3102","volume":"139","author":"G Voiriot","year":"2011","unstructured":"Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest. 2011;139:387\u201394.","journal-title":"Chest"},{"key":"1813_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bcp.14514","volume":"87","author":"R Vaja","year":"2021","unstructured":"Vaja R, Chan JSK, Ferreira P, Harky A, Rogers LJ, Gashaw HH, et al. The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections. Br J Clin Pharmacol. 2021;87:776\u201384.","journal-title":"Br J Clin Pharmacol"},{"key":"1813_CR11","doi-asserted-by":"publisher","first-page":"e2013880","DOI":"10.1001\/jamanetworkopen.2020.13880","volume":"3","author":"LC Lund","year":"2020","unstructured":"Lund LC, Reilev M, Hallas J, Kristensen KB, Thomsen RW, Christiansen CF, et al. Association of nonsteroidal anti-inflammatory drug use and adverse outcomes among patients hospitalized with influenza. JAMA Netw Open. 2020;3:e2013880.","journal-title":"JAMA Netw Open"},{"key":"1813_CR12","first-page":"e00014","volume":"95","author":"JS Chen","year":"2021","unstructured":"Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, et al. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. J Virol. 2021;95:e00014\u201321.","journal-title":"J Virol"},{"key":"1813_CR13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383:2255\u201373.","journal-title":"N Engl J Med"},{"key":"1813_CR14","doi-asserted-by":"publisher","first-page":"m1086","DOI":"10.1136\/bmj.m1086","volume":"368","author":"M Day","year":"2020","unstructured":"Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086.","journal-title":"BMJ"},{"key":"1813_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061959","author":"MH Choi","year":"2020","unstructured":"Choi MH, Ahn H, Ryu HS, Kim B-J, Jang J, Jung M, et al. Clinical characteristics and disease progression in early-stage COVID-19 patients in South Korea. J Clin Med Res. 2020. https:\/\/doi.org\/10.3390\/jcm9061959.","journal-title":"J Clin Med Res"},{"key":"1813_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859\u201366.","journal-title":"Ann Rheum Dis"},{"key":"1813_CR17","doi-asserted-by":"publisher","first-page":"1259.e5","DOI":"10.1016\/j.cmi.2020.06.003","volume":"26","author":"E Rinott","year":"2020","unstructured":"Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26:1259.e5-1259.e7.","journal-title":"Clin Microbiol Infect"},{"key":"1813_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082586","author":"E Bruce","year":"2020","unstructured":"Bruce E, Barlow-Pay F, Short R, Vilches-Moraga A, Price A, McGovern A, et al. Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med Res. 2020. https:\/\/doi.org\/10.3390\/jcm9082586.","journal-title":"J Clin Med Res"},{"key":"1813_CR19","doi-asserted-by":"publisher","first-page":"e1003308","DOI":"10.1371\/journal.pmed.1003308","volume":"17","author":"LC Lund","year":"2020","unstructured":"Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study. PLoS Med. 2020;17:e1003308.","journal-title":"PLoS Med"},{"key":"1813_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/cts.12904","volume":"13","author":"K Kragholm","year":"2020","unstructured":"Kragholm K, Gerds TA, Fosb\u00f8l E, Andersen MP, Phelps M, Butt JH, et al. Association between prescribed ibuprofen and severe COVID-19 Infection: a nationwide register-based cohort study. Clin Transl Sci. 2020;13:1103\u20137.","journal-title":"Clin Transl Sci"},{"key":"1813_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40121-020-00363-w","volume":"10","author":"LC Abu Esba","year":"2021","unstructured":"Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther. 2021;10:253\u201368.","journal-title":"Infect Dis Ther"},{"key":"1813_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1620\/tjem.252.73","volume":"252","author":"NM Alamdari","year":"2020","unstructured":"Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality risk factors among hospitalized COVID-19 patients in a Major Referral Center in Iran. Tohoku J Exp Med. 2020;252:73\u201384.","journal-title":"Tohoku J Exp Med"},{"key":"1813_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/art.41593","volume":"73","author":"JS Chandan","year":"2021","unstructured":"Chandan JS, Zemedikun DT, Thayakaran R, Byne N, Dhalla S, Acosta-Mena D, et al. Nonsteroidal antiinflammatory drugs and susceptibility to COVID-19. Arthritis Rheumatol. 2021;73:731\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"1813_CR24","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s10072-020-04541-z","volume":"41","author":"J-M Hwang","year":"2020","unstructured":"Hwang J-M, Kim J-H, Park J-S, Chang MC, Park D. Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci. 2020;41:2317\u201324.","journal-title":"Neurol Sci"},{"key":"1813_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/joim.13119","volume":"288","author":"Z Imam","year":"2020","unstructured":"Imam Z, Odish F, Gill I, O\u2019Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288:469\u201376.","journal-title":"J Intern Med"},{"key":"1813_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1358863X211012754","volume":"26","author":"A Sahai","year":"2021","unstructured":"Sahai A, Bhandari R, Godwin M, McIntyre T, Chung MK, Iskandar J-P, et al. Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vasc Med. 2021;26:626\u201332.","journal-title":"Vasc Med"},{"key":"1813_CR27","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2665-9913(21)00104-1","volume":"3","author":"TM Drake","year":"2021","unstructured":"Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021;3:e498-506.","journal-title":"Lancet Rheumatol"},{"key":"1813_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219517","author":"AY Wong","year":"2021","unstructured":"Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219517.","journal-title":"Ann Rheum Dis"},{"key":"1813_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","volume":"28","author":"MA Haendel","year":"2021","unstructured":"Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28:427\u201343.","journal-title":"J Am Med Inform Assoc"},{"key":"1813_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jamia\/ocu023","volume":"22","author":"EA Voss","year":"2015","unstructured":"Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22:553\u201364.","journal-title":"J Am Med Inform Assoc"},{"key":"1813_CR31","doi-asserted-by":"publisher","unstructured":"Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.01.12.21249511","DOI":"10.1101\/2021.01.12.21249511"},{"key":"1813_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-0040-1721481","volume":"12","author":"C Maier","year":"2021","unstructured":"Maier C, Kapsner LA, Mate S, Prokosch H-U, Kraus S. Patient cohort identification on time series data using the OMOP common data model. Appl Clin Inform. 2021;12:57\u201364.","journal-title":"Appl Clin Inform"},{"key":"1813_CR33","first-page":"574","volume":"216","author":"G Hripcsak","year":"2015","unstructured":"Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574\u20138.","journal-title":"Stud Health Technol Inform"},{"key":"1813_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"1813_CR35","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192\u2013197."},{"key":"1813_CR36","doi-asserted-by":"publisher","first-page":"e2116901","DOI":"10.1001\/jamanetworkopen.2021.16901","volume":"4","author":"TD Bennett","year":"2021","unstructured":"Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US National COVID Cohort Collaborative. JAMA Netw Open. 2021;4:e2116901.","journal-title":"JAMA Netw Open"},{"key":"1813_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"1813_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/atm.2016.08.57","volume":"5","author":"Z Zhang","year":"2017","unstructured":"Zhang Z. Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med. 2017;5:7.","journal-title":"Ann Transl Med"},{"key":"1813_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40264-021-01089-5","volume":"44","author":"N Moore","year":"2021","unstructured":"Moore N, Bosco-Levy P, Thurin N, Blin P, Droz-Perroteau C. NSAIDs and COVID-19: a systematic review and meta-analysis. Drug Saf. 2021;44:929\u201338.","journal-title":"Drug Saf"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-022-01813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-022-01813-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-022-01813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T02:20:57Z","timestamp":1652581257000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-022-01813-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1186\/s12985-022-01813-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.13.21255438","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol #IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Katie Rebecca Bradwell: employee of Palantir Technologies; Melissa A. Haendel: co-founder Pryzm Health; Julie A. McMurry: Cofounder, Pryzm Health; Jasvinder Singh: JAS has received consultant fees from Crealta\/Horizon, Medisys, Fidia, PK Med, Two labs Inc, Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in TPT Global Tech, Vaxart pharmaceuticals and Charlotte\u2019s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking and Moderna pharmaceuticals. JAS is on the speaker\u2019s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}